Executive Management

Kevin Sayer is the Chairman of the Board of Directors and the Chief Executive Officer of Dexcom

Kevin assumed the role of CEO in January 2015 and became Chairman of the Board in July 2018. Kevin also served as our President from 2011 until May 2025. He held the role of Chief Operating Officer from January 2013 until January 2015. Kevin has served as a member of Dexcom’s Board of Directors beginning in November 2007, prior to his role as Chairman and CEO.

Prior to leading Dexcom, Kevin held various management positions in his prior roles. He served as Chief Financial Officer of Biosensors International Group, Ltd., Executive Vice President and Chief Financial Officer of Specialty Laboratories, Inc., Chief Financial Officer of MiniMed, Inc., and Vice President and General Manager of Medtronic MiniMed after the acquisition of MiniMed by Medtronic.

Kevin is a Certified Public Accountant (inactive) and received a Bachelor’s degree and a Master's degree in Accounting and Information Systems from Brigham Young University.

Jacob (“Jake”) Leach currently serves as our President and Chief Operating Officer at Dexcom. Prior to becoming Chief Operating Officer, Jake served as Chief Technology Officer, leading Dexcom’s research, product development, project management and engineering departments.

Jake is responsible for all things product, driving day-to-day decision-making and resource allocation across all major product-facing groups, including global operations, research and development, clinical affairs, and quality management and regulatory. He is also responsible for creating an integrated management structure that strengthens the company’s ability to execute on its vision for long-term sustainable growth.

Jake joined Dexcom in 2004, and for almost 20 years has helped lead technology development at Dexcom. During his tenure, Jake, together with his team, has ensured Dexcom delivers innovative continuous glucose monitoring solutions paired with exceptional experiences to patients, caregivers, and physicians all over the world. Jake and his team are also responsible for the development of the first commercial Dexcom CGM system, and all future generations, including Dexcom G6, the best-selling real-time CGM in the world.

Jake holds a Bachelor of Science degree in Electrical Engineering with a minor in Biomedical Engineering from the University of California, Los Angeles.

Donald (“Don”) Abbey is Executive Vice President, Global Business Services, IT, Quality and Regulatory Affairs

Don assumed the role of Executive Vice President, Global Business Services, IT, Quality and Regulatory Affairs in January 2017, and previously served as Executive Vice President, Quality from May 2016 to January 2017.

Don has 30+ years of medical device and pharmaceutical industry experience. Prior to Dexcom, Don served in executive roles for Becton Dickinson (the acquirer of CareFusion which itself was spun off from Cardinal Health), including as Senior Vice President, Quality and Regulatory for Becton Dickinson, as Executive Vice President, Quality, Regulatory and Medical Affairs for CareFusion, as Senior Vice President, Quality and Regulatory for CareFusion, and as Senior Vice President, Quality and Regulatory for Cardinal Health. Prior to 2007, Don held senior quality and regulatory affairs and general management positions with Respironics, Welch Allyn, and Philips Healthcare.

Don received a Bachelor of Science degree in Electrical Engineering from Washington State University and a Master of Business Administration from the University of Washington.

Michael Brown is Executive Vice President and Chief Legal Officer at Dexcom, where he has worldwide responsibility for all legal and intellectual property matters.

Before joining Dexcom in 2022, Michael was a partner at DLA Piper, where he served as outside general counsel to companies, advised on important business and legal issues, assisted with corporate governance and executed mergers and acquisitions and financings. Prior to that, he was a partner at Stradling Yocca Carlson & Rauth, where he represented emerging and public technology, life science and other growth companies. Before that, Michael served as outside General Counsel for several high-growth companies.

Michael earned his J.D. from the University of Virginia School of Law and his B.A. from the University of Washington. Michael is a board member of Riding on Insulin, a non-profit organization that connects the global diabetes community through action sports.

Jon Coleman is Executive Vice President and Chief Commercial Officer at Dexcom.

Jon joined Dexcom in 2025 and is responsible for Dexcom’s global commercial organization including global sales, marketing and customer experience.

With over 30 years of experience leading global commercial teams across multiple healthcare segments and channels, Jon has an established track record of scaling operations, developing innovative products, entering new markets, and delivering strong growth performance.

Prior to Dexcom, Jon served as an executive officer of Masimo Corporation, where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo’s commercial teams where he oversaw the consolidation of its worldwide hospital sales, OEM, alternate care sales, and clinical teams along with the customer service and hospital conversion teams. Jon also held significant roles at Pfizer’s Consumer Healthcare business, leading as vice president and general manager of Canada and the Caribbean region after several years of regional leadership in Asia and Latin America.

Since 2018, Jon has been a member of the Board of Trustees for Providence St. Joseph Hospital in Orange, California.

Jon earned an M.B.A. from Harvard Business School and a Bachelor of Arts degree in International Relations from Brigham Young University.

Matt Dolan has served as Dexcom’s Executive Vice President of Strategy, Corporate Development & Dexcom Labs since September 2022.

Matt joined Dexcom in 2015 and has held various positions of increasing responsibility. In his current role, Matt is responsible for Dexcom’s corporate strategy and development functions, including long-range planning, strategic and competitive intelligence, partnerships, and M&A. Since its inception in 2019, he also oversees Dexcom’s New Markets incubator, which is focused on expanding the company’s value proposition across new areas of growth for both its Continuous Glucose Monitoring and other sensing capabilities. Before that, Matt’s responsibilities included support of Dexcom’s Investor Relations efforts.

With 20 years of experience in the medical technology space, Matt began his career as an equity analyst on Wall Street, a role he held for 10 years. After that, he held a leadership position in strategy and business development at Volcano Corporation through the company’s acquisition by Philips in 2015.

Matt earned a Bachelor’s degree in Economics/Pre-Medicine from Northwestern University.

Sadie Stern is Executive Vice President and Chief Human Resources Officer at Dexcom.

In this role, Sadie is responsible for Dexcom’s People Strategy. She leads the Global Human Resources function, including Diversity, Equity and Inclusion; Total Rewards; Talent Acquisition; Talent Development; Organization Effectiveness; and HR Operations. She also serves as the strategic business partner to Dexcom’s Executive Committee.

With more than 20 years of experience in Human Resources, she has led global organizations through growth and change. Prior to Dexcom, she served as Executive Vice President, People and Culture at 3D Systems, overseeing all aspects of Human Resources across the company’s operations in 23 countries. Sadie has also worked at Qualcomm, LG Electronics and The Walt Disney Company, leading HR teams and driving organizational transformation.

She holds a Master of Arts in Higher Education from the University of Denver, and a Bachelor of Arts in English from San Diego State University.

Jereme Sylvain is Executive Vice President and Chief Financial Officer at Dexcom.

In this role, Jereme is responsible for Dexcom’s Finance organization and Investor Relations. He previously served as Dexcom’s Senior Vice President of Finance and Chief Accounting Officer and Vice President, Finance and Corporate Controller.

Prior to Dexcom, Jereme held various positions at NuVasive, Inc., including Chief Accounting Officer, Vice President, Finance and Vice President and Corporate Controller. In these roles, he was responsible for NuVasive’s global accounting function, corporate FP&A, treasury, and shared service functions. Jereme has also held leadership roles at Thermo Fisher Scientific and was part of the public accounting firm Ernst & Young LLP.

Jereme received his Certified Public Accounting license after receiving a Bachelor of Science degree in Finance from Arizona State University and a Master of Science in Accountancy from the University of Notre Dame.